A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo

Journal of Virology

Volumn 72, Issue 3, 1998, Pages 2040-2046

  Chargelegue, Daniel ^a,c   Obeid, Obeid E ^a   Hsu, Shiou Chih ^a   Shaw, Michael D ^a,d   Denbury, Andrew N ^a   Taylor, Geraldine ^b   Steward, Michael W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; VIRUS FUSION PROTEIN;

AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; DNA LIBRARY; IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS LOAD;

EID: 0031935029     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.3.2040-2046.1998     Document Type: Article

References (46)

1. Alwan, W. H., W. J. Kozlowska, and P. J. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89.
2. Alwan, W. H., F. M. Record, and P. J. Openshaw. 1992. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin. Exp. Immunol. 88:527-536.
3. Arbiza, J., G. Taylor, J. A. Lopez, J. Furze, S. Wyld, P. Whyte, E. J. Stott, G. Wertz, W. Sullender, and M. Trudel. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73: 2225-2234.
4. Bourgeois, C., C. Corvaisier, J. B. Bour, E. Kohli, and P. Pothier. 1991. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J. Gen. Virol. 72:1051-1058.
5. Chanock, R. M., R. H. Parrott, M. Connors, P. L. Collins, and B. R. Murphy. 1992. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 90: 137-143.
6. Chargelegue, D., O. E. Obeid, D. M. Shaw, A. N. Denbury, P. Hobby, S. C. Hsu, and M. W. Steward. 1997. Peptide mimics of conformationally constrained epitopes of RSV fusion protein. Immunol. Lett. 57:15-17.
7. Chen, Y. C., K. Delbrook, C. Dealwis, L. Mimms, I. K. Mushahwar, and W. Mandecki. 1996. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc. Natl. Acad. Sci. USA 93:1997-2001.
8. Connors, M., P. L. Collins, C.-Y. Firestone, and B. R. Murphy. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
9. Connors, M., A. B. Kulkarni, C. Y. Firestone, K. L. Holmes, H. C. Morse, A. V. Sotnikov, and B. R. Murphy. 1992. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66:7444-7451.
10. Crowe, J. E. J., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
11. Crowe, J. E. J., P. T. Bui, C. Y. Firestone, M. Connors, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1996. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J. Infect. Dis. 173:829-839.
12. Crowe, J. E. J., B. R. Murphy, R. M. Chanock, R. A. Williamson, C. F. Barbas, and D. R. Burton. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91:1386-1390.
13. Everitt, D. E., C. B. Davis, K. Thompson, R. DiCicco, B. Ilson, S. G. Demuth, D. J. Herzyk, and D. K. Jorkasky. 1996. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J. Infect. Dis. 174:463-469.
14. Francis, M. J., G. Z. Hastings, F. Brown, J. McDermed, Y. A. Lu, and J. P. Tam. 1991. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus. Immunology 73:249-254.
15. Gershoni, J. M., B. Stern, and G. Denisova. 1997. Combinatorial libraries, epitope structure and the prediction of protein conformations. Immunol. Today 18:108-110.
16. Graham, B. S., L. A. Bunton, P. F. Wright, and D. T. Karzon. 1991. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88:1026-1033.
17. Graham, B. S., M. D. Perkins, P. F. Wright, and D. T. Karzon. 1988. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26:153-162.
18. Groothuis, J. R., E. A. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, and the Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
19. Hall, C. B. 1994. Prospects for a respiratory syncytial virus vaccine. Science 265:1393-1394.
20. Hancock, G. E., D. J. Speelman, P. J. Frenchick, M. M. Mineo-Kuhn, R. B. Baggs, and D. J. Hahn. 1995. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection. Vaccine 13:391-400.
21. Hsu, S. C., D. Chargelegue, and M. W. Steward. Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide. Virology, in press.
22. Lam, K. S., S. E. Salmon, E. M. Hersh, V. J. Hruby, W. M. Kazmierski, and R. J. Knapp. 1991. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354:82-84.
23. Lopez, J. A., D. Andreu, C. Carreno, P. Whyte, G. Taylor, and J. A. Melero. 1993. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J. Gen. Virol. 74:2567-2577.
24. Lounsbach, G. R., C. Bourgeois, W. H. West, J. W. Robinson, M. J. Carter, and G. L. Toms. 1993. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli. J. Gen. Virol. 74:2559-2565.
25. Murphy, B. R., G. A. Prince, E. E. Walsh, H. W. Kim, R. H. Parrott, V. G. Hemming, W. J. Rodriguez, and R. M. Chanock. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
26. Nardin, K. H., G. A. Oliveira, J. M. Calvo-Calle, and R. S. Nussenzweig. 1995. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Adv. Immunol. 60:105-149.
27. Obeid, O. E., C. D. Partidos, C. R. Howard, and M. W. Steward. 1995. Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B-and T-cell epitopes from the fusion protein of measles virus. J. Virol. 69:1420-1428.
28. Power, U. F., H. Plotnicky-Gilquin, T. Huss, A. Robert, M. Trudel, S. Stahl, M. Uhlen, T. N. Nguyen, and H. Binz. 1997. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230:155-166.
29. Prince, G. A., V. G. Hemming, R. L. Horswood, and R. M. Chanock. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3:193-206.
30. Saunal, H., and M. H. Van-Regenmortel. 1995. Kinetic and functional mapping of viral epitopes using biosensor technology. Virology 213:462-471.
31. Scott, J. K., and G. P. Smith. 1990. Searching for peptide ligands with an epitope library. Science 249:386-390.
32. Shaw, D. M. 1994. The immunogenicity and protective capacity of synthetic peptide vaccines comprising epitopes from the surface glycoproteins of respiratory syncytial virus. Ph.D. dissertation. London University, London, United Kingdom.
33. Shaw, D. M., C. M. Stanley, C. D. Partidos, and M. W. Steward. 1993. Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization. Mol. Immunol. 30:961-968.
34. Steward, M. W., and D. Chargelegue. 1997. Overview. Antibody affinity: measurement and biological significance, p. 38.1-38.37. In D. M. Weir, L. A. Herzenberg, and C. C. Blackwell (ed.), Handbook of experimental immunology, 5th ed. Blackwell Science, Oxford, United Kingdom.
35. Steward, M. W., C. M. Stanley, and O. E. Obeid. 1995. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J. Virol. 69:7668-7673.
36. Stott, E. J., G. Taylor, L. A. Ball, K. Anderson, K. K. Young, A. M. King, and G. W. Wertz. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855-3861.
37. Tam, J. P. 1988. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 85:5409-5413.
38. Taylor, G. The role of antibody in controlling and/or clearing virus infections, p. 18-35. In G. L. Ada (ed.), Strategies in vaccine design - 1994. R. G. Landes Co., London, United Kingdom.
39. Taylor, G., E. J. Stott, J. Furze, J. Ford, and P. Sopp. 1992. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J. Gen. Virol. 73:2217-2223.
40. Taylor, G., E. J. Stott, M. Hughes, and A. P. Collins. 1984. Respiratory syncytial virus infection in mice. Infect. Immun. 43:649-655.
41. Trudel, M., F. Nadon, C. Seguin, S. Brault, Y. Lusignan, and S. Lemieiu. 1992. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10:107-112.
42. Trudel, M., E. J. Stott, G. Taylor, D. Oth, G. Mercier, F. Nadon, C. Seguin, C. Simard, and M. Lacroix. 1991. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch. Virol. 117:59-71.
43. Valadon, P., G. Nussbaum, L. F. Boyd, D. H. Margulies, and M. D. Scharff. 1996. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 261:11-22.
44. Walsh, E. E. 1994. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J. Infect. Dis. 170:345-350.
45. Wertz, G. W., and M. W. Sullender. 1992. Approaches to immunization against respiratory syncytial virus, p. 151-176. In R. W. Eltis (ed.), Vaccines: new approaches to immunological problems - 1992. Butterworth-Heinemann, Boston, Mass.
46. Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon. 1995. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:543-550.